Comparative Pharmacology
Head-to-head clinical analysis: GVS versus NEOMYCIN AND POLYMYXIN B SULFATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GVS versus NEOMYCIN AND POLYMYXIN B SULFATE.
GVS vs NEOMYCIN AND POLYMYXIN B SULFATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
GVS is not a recognized drug. No mechanism of action available.
Neomycin is an aminoglycoside antibiotic that binds to the 30S ribosomal subunit, causing misreading of mRNA and inhibiting protein synthesis. Polymyxin B sulfate is a cationic detergent that disrupts bacterial cell membrane permeability by interacting with phospholipids, leading to cell death.
1 mg IV bolus every 3 minutes up to 3 doses as needed for status epilepticus; max total dose 3 mg.
For irrigation of urinary bladder: 1 mL of solution containing 40 mg neomycin and 200,000 units polymyxin B per mL diluted in 1 liter of 0.9% sodium chloride, instilled via continuous irrigation at a rate of 1 liter per 24 hours. For topical use: apply thin layer to affected area 2-4 times daily.
None Documented
None Documented
Terminal half-life: 3-5 hours in healthy adults; prolonged to 8-12 hours in severe renal impairment (CrCl <30 mL/min).
Neomycin: 2-3 hours (normal renal function), prolonged to 24-48 hours in renal impairment; Polymyxin B: 4.5-6 hours (normal renal function), extended significantly in renal failure.
Renal: 70% unchanged; biliary/fecal: 20% as metabolites; 10% other.
Renal: ~90-95% (neomycin, polymyxin B) unchanged; fecal: 5-10% (biliary excretion negligible).
Category C
Category A/B
Aminoglycoside Antibiotic
Aminoglycoside Antibiotic